The facility is expected to produce anemia and HIV drugs faster.
Multinational pharmaceutical company GlaxoSmithKlyne (GSK) launched two new manufacturing continuous facility and an expanded production building at its Jurong site.
According to GSK, the new and expanded sites will allow the faster production of drugs and Active Pharmaceutical Ingredients (APIs) for clinical trials.
The expansion also reportedly streamlines the manufacturing of APIs which are important for the production of Dolutegravir (Tivicay), a medication used for HIV/AIDS.
Daprodustat, a new oral drug for treating anaemia associated with chronic kidney disease, will reportedly be the first New Chemical Entity to be developed in the facility. GSK expects the new manufacturing process to reduce Daprodustat’s production time.
Do you know more about this story? Contact us anonymously through this link.